KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$0.8.

  • Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) fell 21594.2% to -$0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.34, marking a year-over-year decrease of 13177.57%. This contributed to the annual value of $1.32 for FY2024, which is 649997.6% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.8, which was down 21594.2% from $0.4 recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $0.69 for Q3 2024, and its period low was -$0.8 during Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $0.14 (recorded in 2022), while the average stood at $0.14.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 190000.0% in 2024, then plummeted by 952064.45% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then soared by 950.0% to $0.42 in 2022, then crashed by 95.24% to $0.02 in 2023, then surged by 1273.96% to $0.27 in 2024, then tumbled by 391.13% to -$0.8 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.8 in Q3 2025, compared to $0.4 in Q2 2025 and -$0.21 in Q1 2025.